Teva Pharmaceutical Industries' share price tumbles after release of 2025 guidance, but analysts remain positive due to investment in innovative pipeline and debt reduction.

Original article source: https://en.globes.co.il/en/article-analysts-remain-positive-on-teva-1001501006
Source Id: 8528501304